Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:49:53 EDT Tue 14 May 2024
Enter Symbol
or Name
USA
CA



Imagin Medical Inc (2)
Symbol IME
Shares Issued 10,830,116
Close 2023-11-17 C$ 0.045
Market Cap C$ 487,355
Recent Sedar Documents

Imagin completes $80,000 note transaction with Bigger

2023-11-20 16:23 ET - News Release

Subject: Imagin Medical - News Release PDF Document File: Attachment 2023 - IME - News Release - Bigger Loan - Nov 2023 (03215432x9DEBD) - FINAL.pdf Imagin Medical Announces $80,000 Financing from Bigger Capital, LP Innovative Cancer Treatment Company Receives Additional Funding Vancouver, British Columbia - November 20, 2023 Imagin Medical Inc. ("Imagin") which is developing the innovative enCAGETM Coil Precision Ablation System and the i/BlueTM Imaging System for the treatment of prostate cancer and bladder cancer respectively today announced the completion of a $80,000 Note transaction with Bigger Capital Fund, LP. In consideration of the loan, Imagin has issued the lender 666,666 share purchase warrants, each exercisable at US$0.40 per share for a period of five years. The proceeds will be utilized for general corporate purposes. About Imagin Medical Imagin Medical is building a best-in-class Urologic Oncology company developing proprietary technologies to better visualize and treat urologic cancers, including bladder and prostate cancer through minimally invasive surgery. The Company believes the i/Blue Imaging System, with its advanced proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting bladder cancer. The enCAGE Coil Prostate Cancer Precision Ablation System, a focal therapy bipolar radio frequency-based probe enabling precise pre-set margins that addresses the limitations of other forms of prostate cancer treatment that lack the ability to precisely target only the cancer cells improve outcomes and quality of life. Learn more at www.imaginmedical.com. Media and Investor Contacts Jim Hutchens, President & CEO, jhutchens@imaginmedical.com John Vacha, Vice President & CFO, jvacha@imaginmedical.com {03215432;1} Word Document File: '\\swfile\EmailIn\20231120 130344 Attachment 2023 - IME - News Release - Bigger Loan - Nov 2023 (03215432x9DEBD) - FINAL.docx' {03215432;1} Imagin Medical Announces $80,000 Financing from Bigger Capital, LP Innovative Cancer Treatment Company Receives Additional Funding Vancouver, British Columbia - November 20, 2023 - Imagin Medical Inc. ("Imagin") which is developing the innovative enCAGE(TM) Coil Precision Ablation System and the i/Blue(TM) Imaging System for the treatment of prostate cancer and bladder cancer respectively today announced the completion of a $80,000 Note transaction with Bigger Capital Fund, LP. In consideration of the loan, Imagin has issued the lender 666,666 share purchase warrants, each exercisable at US$0.40 per share for a period of five years. The proceeds will be utilized for general corporate purposes. About Imagin Medical Imagin Medical is building a best-in-class Urologic Oncology company developing proprietary technologies to better visualize and treat urologic cancers, including bladder and prostate cancer through minimally invasive surgery. The Company believes the i/Blue Imaging System, with its advanced proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting bladder cancer. The enCAGE Coil Prostate Cancer Precision Ablation System, a focal therapy bipolar radio frequency-based probe enabling precise pre-set margins that addresses the limitations of other forms of prostate cancer treatment that lack the ability to precisely target only the cancer cells improve outcomes and quality of life. Learn more at www.imaginmedical.com. Media and Investor Contacts Jim Hutchens, President & CEO, jhutchens@imaginmedical.com John Vacha, Vice President & CFO, jvacha@imaginmedical.com

© 2024 Canjex Publishing Ltd. All rights reserved.